ClinicalTrials.gg
Not yet recruitingNCT07364916Updated Jan 23, 2026

Effect of Water Flossing on Gingival Inflammation Around Single Implants

An interventional study of Water flosser and Tooth brush and string floss in Peri Implant Mucositis, sponsored by King Abdulaziz University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by King Abdulaziz University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effect of water floss in reversing peri- implant mucositis around dental implants

Read the detailed description

Patients will be assigned for two clinical appointments, the first visit is for baseline charting, probing depth will be recorded on six sites per implant, using a standardized periodontal probe and the presence or absence of bleeding will be recorded. Disclosing tablets will be utilized to

Confirm the presence or absence of plaque around teeth and the implant. Patients (Group A) will be given a water floss, with verbal and written instructions to use the water floss, twice daily for 2 minutes, along with brushing, while Group B will be instructed to brush with a manual brush alone, twice daily for 2 minutes. After two weeks, in the second visit, the implant site is re-evaluated to monitor the outcomes.

02

Conditions studied

  • Peri Implant Mucositis

Browse trials for

Keywords

  • Peri- implant
  • Mucositis
  • Water irrigation
  • Water flosser
03

In context

Mucositis

265 studies on the registry are indexed under Mucositis; 34 are open to participants now.

This study's planned enrollment of 20 is below the median of 45 across 215 interventional studies indexed under Mucositis.

Browse Mucositis studies →

Lead sponsor

King Abdulaziz University is the lead sponsor of 98 studies on the registry; 19 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Medically cleared
  • Have at least one implant-supported crown.

Exclusion criteria

Exclusion Criteria:

  1. Smoking
  2. Any systemic or localized illness that would interfere with dental implant therapy
  3. On medications
  4. Pregnancy
  5. History of periodontitis/ or peri-implant disease
  6. Poor oral hygiene
  7. Probing depth is >5
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Water flosser

    The use of a water flosser+ brushing around implants with mucositis

    Device: Water flosser

  • Active comparator
    Control

    Brushing and using the string floss.

    Device: Tooth brush and string floss

Interventions

  • DeviceWater flosser

    Water irrigation device

  • DeviceTooth brush and string floss

    The control group will use the toothbrush and the regular string floss.

06

What researchers measure

Primary outcomes

  1. Bleeding on Probing

    The disappearance of bleeding upon probing with the University of North Carolina-15 mm (UNC-15) periodontal probe. It is done at the same time as probing the pocket depths. It is done at six sites per implant-presence of bleeding = 1, absence = 0 -at each site.

    Time frame: 2 and 4 weeks

  2. Plaque Index of Silness and Loe

    Score Description 0 No plaque 1 A thin film of plaque adhering to the free gingival margin and adjacent area of the implant; not visible to the naked eye but detectable by probe 2 Moderate accumulation of soft deposits visible to the naked eye within the gingival pocket and/or on the implant and gingival margin \| 3 Abundant soft matter within the gingival pocket and/or on the implant and gingival margin \|

    Time frame: 4 weeks

Secondary outcomes

  1. Probing Pocket Depths (PPD)

    The PPD will be recorded at baseline visit using the UNC-15 periodontal probe, at 2 weeks, and at 4 weeks. Pocket depths around implants should usually be around 1-4 mm. Pockets that are deeper than 4 mm or are 4 mm or less but with bleeding will be recorded as abnormal.

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to de-identified individual participant data will be granted to qualified researchers who submit a scientifically sound proposal outlining the research objectives and planned analyses. Requests will be reviewed by the principal investigator to ensure alignment with the original study aims, ethical approval, and data protection requirements. Approved applicants will be required to sign a data use agreement prior to data release. Data will be provided in a secure, de-identified format and used solely for the approved purpose.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: IPD will be available beginning 6 months after publication of the primary results and will remain available for up to 5 years thereafter.

Access criteria: Requests for access to the IPD should be directed to the corresponding author. Data will be shared in a secure format following approval of the request and execution of a data use agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for May 2026, 4 months later.

Of 67 non-industry interventional studies with no phase under Mucositis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 26. This study's planned 4 months is below that.

Counting every sponsor, half of 70 studies reached it within 12 months; a quarter within 6 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2025
First posted
Jan 23, 2026
StartEst.
Jan 1, 2026
Primary completionEst.
May 31, 2026
CompletionEst.
Sep 30, 2026
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07364916
Lead sponsor
King Abdulaziz University
Responsible party
Amal Jamjoom, BDS, MS. (Assistant Professor at KAU, King Abdulaziz University) — Principal investigator
First posted
Jan 23, 2026
Start date
Jan 1, 2026 (estimated)
Primary completion
May 31, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jan 23, 2026

Study contacts

Amal Jamjoom, BDS, MS
Contact
agjamjoom@kau.edu.sa
+966500190435
Amal G Jamjoom, MS
Contact
agjamjoom@kau.edu.sa
0500190435
Amal G Jamjoom
principal investigator · King Abdulaziz University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion